Chronic myelomonocytic leukemia in the light of the WHO proposals

Authors:
  • CSC. Strupp
    C. Strupp
  • SKS. Knipp
    S. Knipp
  • AKA. Kuendgen
    A. Kuendgen
  • AGA. Giagounidis
    A. Giagounidis
  • BHB. Hildebrandt
    B. Hildebrandt
  • CAC. Aul
    C. Aul
  • RHR. Haas
    R. Haas
  • NGN. Gattermann
    N. Gattermann
  • JBJ. M. Bennett
    J. M. Bennett
Publisher website
Google Scholar
Abstract
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (pp=0.001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classification of CMML.